2017
successfully listed on the Shenzhen Stock Exchange
2015
passed the FDA on-site inspection
2013
Pass EDQM GMP inspection for Losartan Potassium
2011
Obtain CEP certificate from EDQM, and GMP from Chinese-FDA for Valsartan and Irbesartan.
2006
The output of “Sartan” series products exceeds 50 MT.
2005
Obtain drug manufacturing license certificate from Chines-FDA and submit the 1st DMF to US-FDA
2003
Start the 1st GMP working shop operation